These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33393598)

  • 41. Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract.
    Wang H; Palasik BN
    Ther Adv Urol; 2022; 14():17562872211065570. PubMed ID: 35126672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials.
    Portsmouth S; Bass A; Echols R; Tillotson G
    Open Forum Infect Dis; 2021 Mar; 8(3):ofab045. PubMed ID: 33738315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution.
    Morris CP; Bergman Y; Tekle T; Fissel JA; Tamma PD; Simner PJ
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32938734
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial.
    Mir MDA; Chaudhary S; Payasi A; Sood R; Mavuduru RS; Shameem M
    Open Forum Infect Dis; 2019 Oct; 6(10):. PubMed ID: 31433059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
    Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
    BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy.
    Stracquadanio S; Torti E; Longshaw C; Henriksen AS; Stefani S
    J Glob Antimicrob Resist; 2021 Jun; 25():390-398. PubMed ID: 34020073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefiderocol.
    Soriano MC; Montufar J; Blandino-Ortiz A
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):31-34. PubMed ID: 35488822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement.
    Cortegiani A; Ingoglia G; Ippolito M; Girardis M; Falcone M; Pea F; Pugliese F; Stefani S; Viale P; Giarratano A
    J Anesth Analg Crit Care; 2022 Jul; 2(1):34. PubMed ID: 37386663
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
    Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
    BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
    Yusuf E; Bax HI; Verkaik NJ; van Westreenen M
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an
    Matsumoto S; Kanazawa S; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms.
    Sajib MI; Monteforte M; Go R
    Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.